Article
SOS1 and KSR1 modulate MEK inhibitor responsiveness to target resistant cell populations based on PI3K and KRAS mutation status.
Proceedings of the National Academy of Sciences of the United States of America - 21 Nov 2023
Daley Brianna R, Vieira Heidi M, Rao Chaitra, Hughes Jacob M, Beckley Zaria M, Huisman Dianna H, Chatterjee Deepan, Sealover Nancy E, Cox Katherine, Askew James W, Svoboda Robert A, Fisher Kurt W, Lewis Robert E, Kortum Robert L
Abstract excerpt
KRAS is the most commonly mutated oncogene. Targeted therapies have been developed against mediators of key downstream signaling pathways, predominantly components of the RAF/MEK/ERK kinase cascade. Unfortunately, single-agent efficacy of these agents is limited both by intrinsic and acquired resistance. Survival of drug-tolerant persister cells within the heterogeneous tumor population and/or acquired mutations...
Read the complete abstract on PubMedTopics
Share this publication in a Topic to start or enrich a Post.